CBD

Canadian cannabis company Canopy Growth Corp (NYSE: CGC) confirmed Monday that it received a license to produce and process hemp in New York, prompting GMP to turn incrementally bullish on the stock. The Analyst Analyst Martin Landry maintains a Buy rating on Toronto-listed Canopy Growth ...

From companies going public on major exchanges, mergers and acquisitions and full legalization of weed in Canada, 2018 was a transformational year in cannabis. One major milestone for the industry was the passage of the 2018 Farm Bill. Although the bulk of the spending in the bill...

KushCo Holdings Inc (OTC: KSHB), a provider of ancillary products and services to the cannabis industry, reported Q1 results after the close Tuesday. Although the company's revenue almost tripled over the year, its bottom line turned negative. What Happened KushCo posted a revenue $25...

President Donald Trump signed a Farm Bill into law Thursday that includes a provision removing hemp from the Controlled Substances Act. What Happened The 2018 Farm Bill includes provisions that will aid farmers in obtaining crop insurance, according to the administration.  “By signing...

On Dec. 11, the Consumer Analyst Group of New York hosted a group luncheon where Canopy Growth Corp. (NYSE: CGC) CEO Bruce Linton presented. Wells Fargo analysts attended the luncheon and presented their main takeaways. Overall, the analysts said they are optimistic about the company's...

New Age Beverages Corp (NASDAQ: NBEV) shares were trading up again Wednesday on the back of the Senate vote on the 2018 Farm Bill. The news lifted other hemp and CBD companies higher, including Youngevity International Inc (NASDAQ: YGYI) and Pyxus International Inc (NYSE: PYX). New Age shares...

The 2018 Farm Bill, a piece of legislation much anticipated by the hemp sector, is approaching the finish line. The House and Senate members who comprise the Farm Bill Conference Committee have released a final draft and filed the bill. One major highlight: the legalization of the cultivation of...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

A new company is set to join the growing hemp market. MariMed Inc (OTC: MRMD) has agreed to invest $30 million in GenCanna Global as part of a strategic partnership.  What Happened MariMed develops and operates cannabis facilities and branded product lines in several U.S. states....

With global demand for hemp surging, China's sector is poised for years of dramatic growth. In 2017, Chinese hemp sales totaled $1.1 billion (USD), approaching 1/3 of the $3.1 billion global market, with sales forecasted to grow to $1.5 billion (up 36%) by 2020. In 2017, textiles accounted for...

By J.J. McCoy, Senior Managing Editor, New Frontier Data Not that the expanding patchwork of licensing regulations for hemp programs throughout the United States can be confusing and uneven, but had Johnny Appleseed faced all the challenges now confronting prospective American cultivators, he...

By Larry Mishkin, Hoban Law Group, Litigation Practice Group Counsel Last month, Illinois Gov. Bruce Rauner signed into law Senate Bill 2298, the Illinois Industrial Hemp Act, which became effective immediately. The act allows Illinois farmers, in conjunction with a university or other recognized...

In July, the California Department of Public Health's Food and Drug Branch (CDPH-FDB) threw the burgeoning cannabidiol (CBD) industry into some frenzy by issuing a revised FAQ on CBD in food products, declaring that it cannot be added to any, even if it comes from legal hemp. The move thus...

By: William Sumner Have you ever experienced sticker shock? If you're like some of the people following the development of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CBD-based drug, Epidiolex, then odds are you probably have. After gaining approval from the FDA, GW released the estimated price...

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...